BLACKROCK ASSET MANAGEMENT CA LTD ISHARES GENOMICS IMMUNOLOGY AND HEALTHCA (XDNA)
- 56.420
- -0.490-0.86%
BLACKROCK ASSET MANAGEMENT CA LTD ISHARES GENOMICS IMMUNOLOGY AND HEALTHCA (XDNA) News
'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'-
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.• Inhibrx Biosciences stock is taking a hit today. What's behind
8 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Day 3 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Intensive talks on new "-tinib" drugs as star companies such as BeiGene and Kelun Biotech take the stage.
1) Intensive negotiations for new "-tinib" class drugs took place in the morning, with innovative pharmaceutical companies such as InnoCare Pharma, Shouyao Holdings, and Jiangsu Wellshine making successive appearances; 2) In the afternoon session, leading pharmaceutical firms including Kelun Biotech and BeiGene were featured, engaging in a two-pronged strategic dynamic in the ADC sector characterized by "expansion within the catalog" and "new additions outside the catalog."
Day 2 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Two CAR-T therapies vie for basic medical insurance coverage as executives from multiple companies maintain on-site presence.
1. As the national reimbursement drug negotiations entered their second day, several innovative drugs and products with high clinical value were brought to the negotiating table; 2. In line with past practice, innovative drugs that are relatively more difficult to negotiate, such as anti-cancer medications and treatments for rare diseases, tend to be scheduled more intensively in the subsequent days. The lineup of participating companies suggests that this arrangement has largely been maintained.
List of Reversal Stocks (Part 2) [List of Stocks with Parabolic Signal Reversals]
○ List of Stocks Recommended for Sale Market Code Stock Name Closing Price SAR TSE Prime <1332> Nissui 1230 1321 <1333> Umio 1280 1320 <1417> Mirait Holdings 3553 3698 <1719> Ando Hazama 1916 1961 <1762> Takamatsu Construction Group 4125 4320 <1780> Yamaura 1495 1518 <1898> Seiki Tokyu Kogyo 1495 1517 <192
Notable Healthcare Headlines for the Week: UnitedHealth, Moderna, and Medtronic in Focus
On-the-ground report from Day 2 of the 2026 NRDL negotiations: Blockbuster oncology drugs, including CAR-T therapies and the world’s first bispecific antibody-drug conjugate (ADC), made their debut, while products covered by commercial insurance sought to
① On the second day of national reimbursement negotiations, the focus shifted to innovative oncology drugs, with nearly 20 companies—including Hengrui Medicine, Eli Lilly and Co, Novartis, and Innovent Biologics—participating in the morning session; ② In the afternoon, multinational pharmaceutical firms took center stage, with Merck & Co, Roche, and Johnson & Johnson successively entering negotiations as several blockbuster innovative drugs were brought to the table; ③ Companies such as Heyuan Biopharma and JW Therapeutics, which emerged as new entrants in commercial health insurance formularies last year, are once again attempting to break into the basic medical insurance scheme, marking the transition of dual-formulary alignment into the practical implementation phase.
Healthcare August Recap: Moderna Jumps 156% as Biotech Shines; DaVita Sinks
Breakthrough in "Personalized Cancer Vaccines"! "Tumor Sequencing" Takes Center Stage
Breakthroughs in personalized cancer vaccines are driving up demand for tumor sequencing, making related diagnostic companies a new focus of capital markets. Positive trial results from Moderna and Merck have boosted the stock prices of firms such as Tempus AI and sparked a potential bidding war for Personalis. The market remains optimistic about the long-term growth potential of minimal residual disease (MRD) testing, although the industry still faces uncertainties related to clinical validation, commercialization, and competition.
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines
Moderna Ignites Hope: Has the Era of Cancer Vaccines Truly Arrived?
① Moderna’s early success serves as the strongest endorsement for the technological pathway of “personalized neoantigen cancer vaccines”; ② The current bottleneck in the development of neoantigen cancer vaccines no longer lies in delivery or synthesis technologies; rather, the key to success is the precise prediction of tumor mutations; ③ Once it is proven in the adjuvant therapy setting that the product can significantly reduce the risk of postoperative recurrence, its commercial ceiling will be substantially raised.
J-Pharma made the rankings, with buying interest reviving on the back of its transition to an executive officer system.
J-Pharma <520A> has entered the rankings (as of 10:20 a.m.), posting a sharp rebound. Investor interest surged following the September 1 announcement of its transition to an executive officer system. Although the stock underwent consolidation yesterday, buying interest has revived today. The announcement stated that Shinya Hirata, who has experience in ophthalmology and immunological/inflammatory diseases at companies such as Otsuka Pharmaceutical and Takeda Pharmaceutical <4502>, and who served as Executive Officer and Head of R&D at SanBio <4592>, has been appointed to oversee clinical development and regulatory affairs. The stock is also among the top movers in terms of change in trading volume.
Mitsui E&S, Toyota Tsusho, and others [List of stock-related news from newspapers]
* Mitsui E&S <7003> to assemble port cranes in the U.S. at its Seattle base (Nikkan Kogyo, p.1) - ○ * Fujifilm Holdings <4901> to establish a lens development base in Ibaraki for its Optics division, strengthening high-precision products (Nikkan Kogyo, p.1) - ○ * Toyota Tsusho <8015> to increase staff in India by 30% to support Japanese automakers (Nikkan Kogyo, p.1) - ○ * Yamato Holdings <9064> to end domestic cargo flights with JAL Group next year (Nikkan Kogyo, p.3) - ○ * Nichirin <5184> receives recommendation from the Japan Fair Trade Commission for violations of the Subcontracting Act
EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert
Biotech could be entering a broader re-rating as artificial intelligence and genomics accelerate drug discovery, while health care valuations remain at a significant discount to the broader market,
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market.A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.HC
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron